Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director · President and CEO | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 475,000 |
Reported balance
After 2026-03-27 transaction · row 1
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 300,000 · Balance 475,000 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-03-26 | Direct | 600,000 |
Reported balance
After 2026-03-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-27 · Grant · Acquired 600,000 · Balance 600,000 F2: Twenty-five percent (25%) of the shares underlying this option shall vest on March 27, 2027, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F2: Twenty-five percent (25%) of the shares underlying this option shall vest on March 27, 2027, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2026 Filed Mar 31, 2026 16:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0000905148-26-001480 · form4.xml · derivative · entry 2 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2036-03-26 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest on March 27, 2027, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 16:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001480 · form4.xml · nonDerivative · entry 1 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 19:47 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 75,000 | $1.37 | $102,915.00 |
DisclosureSEC source: 0000905148-25-002876 · form4.xml · nonDerivative · entry 1 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 F1 · price: These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 347,500 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000905148-25-000961 · form4.xml · derivative · entry 1 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,500 Underlying: Common Stock · 347,500 shares Expires 2035-03-13 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest on March 14, 2026, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 17:55 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 70,443 | $4.90 | $345,241.14 |
DisclosureSEC source: 0001415889-24-016259 · form4-06102024_090649.xml · nonDerivative · entry 2 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 17:55 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 29,557 | $4.87 | $143,824.36 |
DisclosureSEC source: 0001415889-24-016259 · form4-06102024_090649.xml · nonDerivative · entry 1 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,557 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.84 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-24-000790 · doc4.xml · derivative · entry 1 Masoud Maher · CIK 0001874571 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: This option grant was made pursuant to the terms of the letter agreement, dated as of December 11, 2023, by and between the Issuer and the reporting person, entered into in connection with his appointment as President and Chief Executive Officer of the Issuer, as set forth in a Current Report on Form 8-K filed by the Issuer on December 11, 2023. Of the shares underlying the option, 25% will vest on January 2, 2025 and the remaining 75% will vest in 36 equal monthly installments thereafter, in each case subject to the reporting person's continuous service with the Issuer at the applicable vesting date. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001209191-23-020289 · doc4.xml · derivative · entry 1 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-03-19 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 16:21 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 242,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021481 · doc4.xml · derivative · entry 1 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Common Stock · 242,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,562 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · derivative · entry 11 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,562 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 18,562 | $12.08 | $224,228.96 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 7 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 18,562 | $3.25 | $60,326.50 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 6 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,438 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · derivative · entry 10 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 Underlying: Common Stock · 6,438 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,278 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · derivative · entry 9 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 24,278 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on March 25, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 30,716 | $12.16 | $373,506.56 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 5 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 6,438 | $3.25 | $20,923.50 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 4 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 24,278 | $2.08 | $50,498.24 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 3 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,722 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · derivative · entry 8 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,278 Underlying: Common Stock · 25,722 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on March 25, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 25,722 | $12.66 | $325,640.52 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 2 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 25,722 | $2.08 | $53,501.76 |
DisclosureSEC source: 0001209191-21-064891 · doc4.xml · nonDerivative · entry 1 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:17 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050945 · doc4.xml · derivative · entry 1 Masoud Maher · CIK 0001874571 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.